Martin Wehling - Böcker

Principles of Translational Science in Medicine: From Bench to Bedside, Second Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics.

The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing numbers of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics.

The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine.

Provides an in-depth description of novel tools for the assessment of translatability of trials to balance risk and improve projects at any given stage of product development New chapters deal with translational issues in the fastest growing population (the elderly), case studies, translatability assessment tools, and advances in nanotherapies Details IPR issues of translation, especially for public-private-partnerships Contains contributions from world leaders in translational medicine, including the former NIH director and authorities from various European regulatory institutions

Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing number of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics.

New chapters include: Translation in Oncology, Biologicals, and Orphan Drugs. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine and is written by worldwide experts in their respective fields.

Includes state-of-the-art principles, tools such as biomarkers and early clinical trials, algorithms of translational science in medicine Provides in-depth description of special translational aspects in the currently most successful areas of clinical translation, namely oncology and immunology Covers status of institutionalization of translational medicine, networking structures and outcomes at the level of marketing authorization

Despite advancements in the cloning of the human genome, biomedical innovations at patient level are rare events. Translational medicine is, however, a burgeoning science that shows potential to reverse the trend. This textbook provides a survey of translational medicine, emphasising its emerging scientific backbone, its strengths and weaknesses. It explores all aspects of preclinical and clinical issues relevant to the success of translational pharmaceutical or medical device or diagnostic innovations, including target risk assessment, biomarker evaluation, and predictivity grading for both efficacy and toxicity; early human trial designs, adequate to guide stop or go decisions on the grounds of biomarker panels; and biostatistical methods to analyze multiple readout situations and quantify risk projections. Translational Science in Medicine provides guidance to design profiling strategies for new approaches to the field. By generating dialogue about translational science Wehling explores the implications of this field on the future of patient care.

Neueste Forschungsergebnisse zu extrarenalen Aldosteronwirkungen sind Gegenstand dieses Buches. Die bisherige Forschung hat Mineralkortikoidhormonwirkungen vernachlässigt. In diesem Buch werden sie erstmals am menschlichen Lymphozyten erläutert und interpretiert. Ihr Mechanismus ist an diesem leicht zugänglichen Zellmodell gut zu erforschen. Auch erlaubt das menschliche Lymphozyt entscheidende Einblicke in pathogenetische Vorgänge bei Erkrankungen des Wasser- und Elektrolythaushaltes und den Veränderungen bei den verschiedenen Erkrankungen.

Sichere, aber auch wirksame Arzneitherapie für ältere Patienten!Also nicht nur ungeeignete, sondern vor allem auch geeignete Arzneimittel erkennen!Welche Besonderheiten gibt es?Welche Nebenwirkungen/Wechselwirkungen müssen insbesondere beachtet werden – und können ggfs. als eigenständige Erkrankungen fehlinterpretiert werden? Menschen im Alter über 65 Jahre bilden die am stärksten wachsende Bevölkerungsgruppe.Ältere Patienten haben häufig mehrere - oft chronische – Erkrankungen. Unerwünschte Arzneimittelwirkungen sind überdurchschnittlich häufig u.a. wegen:geänderter biologischer Eckdaten (u.a. Nierenfunktion vermindert, mehr Fett- weniger Muskelmasse)mangelnder AdhärenzVielfachmedikation mit kaum vorhersagbaren Wechselwirkungen Empfehlungen zu allen relevanten Erkrankungen, inkl.SuchterkrankungenWechselwirkungen von Medikamenten mit Lebensmitteln (z.B. Grapefruit) oder mit pflanzlichen Arzneimitteln (z.B. Johanniskrautpräparate). NEU u.a.Neueste Daten, Statistiken, Key EvidencesWertungssystem der Alterstauglichkeit von Arzneimitteln nach FORTA: top-aktuelle Liste nach 3. Delphi-Prozess 2018!Vollständig überarbeitet Choosing wiselyDie Lösungsvorschläge und Antworten für die tägliche Praxis:Medizinische Sicherheit: Welche Medikamente haben Priorität? Was kann/muss ich weglassen?Ökonomische Sicherheit: Bessere Arzneitherapie mit weniger Verschreibungen (= Einhaltung des Arzneimittelbudgets).